Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | THPO | P40225 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9008124 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL14853690 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL12429068 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL14817692 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL10099482 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL13496252 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL13865179 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL15588473 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL16298765 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 | |
| SCHEMBL14536569 | 1.00 | LMNA (0.78) | LMNACYP1A2THPOKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243018-B2 | Synthetic heparin pentasaccharides | DR. REDDY'S LABORATORIES, SA (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150005485-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2015-01-01 | — | — | US | disclosed |
| EP-1440077-B1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LTD (AU) | 2013-05-01 | — | — | EP | disclosed |
| US-20120208993-A1 | SYNTHETIC HEPARIN TRISACCHARIDES | ALCHEMIA LIMITED (AU) | 2012-08-16 | — | — | US | disclosed |
| US-8114970-B2 | Synthetic heparin monosaccharides | ALCHEMIA LIMITED (AU) | 2012-02-14 | — | — | US | disclosed |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2009-07-23 | — | — | US | disclosed |
| US-7541445-B2 | Synthetic heparin pentasaccharides | ALCHEMIA LIMITED (AU) | 2009-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | LMNA 3969/4885CYP1A2 4181/4885THPO 19/4885 |
| US-20150005485-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | LMNA 4043/4885CYP1A2 4289/4885THPO 17/4885 |
| US-20120208993-A1 | SYNTHETIC HEPARIN TRISACCHARIDES | HPSE, SERPINC1, DDOST | LMNA 3666/4885CYP1A2 4181/4885THPO 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.